The drugmaker’s revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines’ speciality portfolio.
The post Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business appeared first on Home Page.
